Capex / expansionFiled on BSE ·
Fredun Pharmaceuticals transitions to branded healthcare and expands pet care
Fredun Pharma · Pharmaceuticals & Biotechnology
What the filing says
- Acquired 26% stake in Goodman Vetcare at ₹300 crore, targeting ₹100 crore revenue by FY31
- Acquired Furlicks pet-wellness brand, expanding product portfolio from 6 to 22 SKUs in 6–9 months
- Allotted 1.10 crore bonus shares on July 17, 2026, increasing share base to 1.65 crore
Original filing
Announcement under Regulation 30 (LODR)-Press Release / Media Release
Read the filing on BSE (PDF) →Companies guiding to strong growth
Ranked by management's own guidance on revenue and margins — not by us.
Waaree Energies
Electrical Equipment
Revenue growth 40%+Margin up 2%+
Sign up free to see all 6 →
See full rankingsRank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
More from Fredun Pharma
Other capex / expansion filings this fortnight
- Capex / expansionKabra Extrusion Technik LtdKabra Extrusiontechnik commissions 10 MW/20 MWh Battery Energy Storage System
- Capex / expansionJubilant Pharmova LtdJubilant Pharmova invests CAD 94.5 million to double RUBY-FILL® capacity
- Capex / expansionBrigade Enterpr.Brigade Group announces ₹40,000 crore investment for 3-year growth plan
- Capex / expansionPower Grid CorpnPower Grid Corporation commissions 2500 MW Solar Transmission Project in Karnataka
- Capex / expansionPolyplex Corporation LtdPolyplex to add 12,000 MT capacity with second-hand film line in Thailand
- Capex / expansionVoltamp Transformers LtdVoltamp Transformers Limited begins commercial production at new plant Unit-III
Summary written by Arthneeti from the company's filing with the stock exchange; check the original filing for full details. Arthneeti is a research and analytics platform, not a SEBI-registered investment adviser, and nothing here is a recommendation to buy or sell.